Private equity (PE) has played an increasing role in health care management in recent years, with total investment increasing from less than $5 billion in 2000 to more than $100 billion in 2018. PE-owned firms provide the staffing for more than one-third of emergency rooms, own large hospital and nursing home chains, and are rapidly expanding ownership of physician practices. This role has raised questions about health care performance as PE-owned firms may have incentives more aligned with firm value than with consumer welfare.

This work focuses on PE and US nursing homes, a sector with spending at $166 billion in 2017 and projected to grow to $240 billion by 2025. Nursing homes have historically had a high rate of for-profit ownership (about 70%), allowing the authors to study the effects of PE ownership relative to for-profit ownership more generally. Also, PE firms have acquired both large chains and independent facilities, enabling the authors to make progress in isolating the effects of PE ownership from the related phenomenon of corporatization in medical care.

The authors employ patient- and facility-level administrative data from the Centers for Medicare & Medicaid Services (CMS), which they match to PE deal data to observe about 7.4 million unique Medicare patients. The data include 18,485 unique nursing homes between 2000 and 2017. Of these, 1,674 were acquired by PE firms in 128 unique deals. Their findings include the following:

  • Going to a PE-owned nursing home increases the probability of death during the stay and the following 90 days by 1.7 percentage points, about 10% of the mean. This estimate implies about 20,150 Medicare lives lost due to PE ownership of nursing homes during the authors’ sample period.
  • The authors estimate a corresponding implied loss in life-years of 160,000. Using a conventional value of a life-year from the literature, this estimate implies a mortality cost of about $21 billion in 2016 dollars, or about twice the total payments made by Medicare to PE facilities during our sample period, about $9 billion.
  • The total amount billed for both the stay and the 90 days following the stay increases by about 11%.
  • Nurse availability per patient declines, and there is an increase in operating costs that tend to drive profits for PE funds.
  • Finally, attending a PE-owned nursing home increases the probability of receiving antipsychotic medications—discouraged in the elderly due to their association with greater mortality—by 50%. Similarly, patient mobility declines and pain intensity increases post-acquisition.

The authors acknowledge that although their results imply that PE ownership reduces productivity of nursing homes, such ownership may have more positive effects in other sectors of healthcare with better functioning markets. Further work is needed to determine how government programs can be redesigned to align the interests of PE-owned firms with those of taxpayers and consumers.

More on this topic

Podcast Nov 12, 2024

Deadly Prescriptions: What Happens When Doctors Compete for Patients

Tess Vigeland and Molly Schnell
When some US states allowed nurse practitioners to prescribe controlled substances without physician oversight, a serious unintended consequence took hold: Doctors found themselves competing with those nurses for patients. Molly Schnell, BFI Saieh Family Fellow and assistant professor at Northwestern...
Topics: Health care
Podcast Oct 15, 2024

How Do Buyouts Impact Hospital Performance? Evaluating the Role of Private Equity in Healthcare

Tess Vigeland and Maggie Shi
Private equity investors made some $200 billion worth of healthcare acquisitions in 2021, and $1 trillion worth in the 10 years leading up to 2023. In this episode of The Pie, Maggie Shi, professor at the Harris School of Public...
Topics: Health care
Research Briefs·Sep 25, 2024

Investing in Vaccines to Mitigate Harm from COVID-19 and Future Pandemics

Rachel Glennerster, Catherine Che, Sarrin Chethik, Claire McMahon, and Christopher M. Snyder
During pandemics, rapid vaccination can significantly reduce mortality, economic losses, and societal disruptions. Vaccine manufacturers often lack incentives to expand their speed and capacity, however. This market failure can be addressed with strategic policies that realign incentives both during and...
Topics: Health care